St. Louis Trust Co Buys Shares of 82,452 CVS Health Corporation $CVS

St. Louis Trust Co bought a new stake in CVS Health Corporation (NYSE:CVS) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 82,452 shares of the pharmacy operator’s stock, valued at approximately $6,543,000. CVS Health comprises about 0.8% of St. Louis Trust Co’s investment portfolio, making the stock its 24th largest holding.

Several other institutional investors have also added to or reduced their stakes in the business. MQS Management LLC acquired a new stake in CVS Health in the fourth quarter worth about $289,000. Associated Banc Corp boosted its holdings in CVS Health by 2.0% in the fourth quarter. Associated Banc Corp now owns 52,530 shares of the pharmacy operator’s stock worth $4,169,000 after acquiring an additional 1,016 shares in the last quarter. New Millennium Group LLC boosted its holdings in CVS Health by 149.3% in the fourth quarter. New Millennium Group LLC now owns 2,037 shares of the pharmacy operator’s stock worth $162,000 after acquiring an additional 1,220 shares in the last quarter. Ruedi Wealth Management Inc. acquired a new stake in CVS Health in the fourth quarter worth about $449,000. Finally, Advisory Alpha LLC boosted its holdings in CVS Health by 5.5% in the fourth quarter. Advisory Alpha LLC now owns 5,345 shares of the pharmacy operator’s stock worth $424,000 after acquiring an additional 277 shares in the last quarter. Institutional investors and hedge funds own 80.66% of the company’s stock.

Insider Buying and Selling

In other CVS Health news, EVP Tilak Mandadi sold 69,551 shares of the business’s stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $89.58, for a total value of $6,230,378.58. Following the completion of the transaction, the executive vice president directly owned 10,133 shares of the company’s stock, valued at approximately $907,714.14. The trade was a 87.28% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, Director Larry Robbins sold 1,983,538 shares of the business’s stock in a transaction that occurred on Tuesday, May 19th. The shares were sold at an average price of $94.45, for a total value of $187,345,164.10. Following the completion of the transaction, the director directly owned 6,213,261 shares of the company’s stock, valued at $586,842,501.45. The trade was a 24.20% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 3,441,551 shares of company stock valued at $323,703,977 over the last three months. 0.85% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the company. Wall Street Zen raised CVS Health from a “hold” rating to a “buy” rating in a report on Saturday, May 9th. Sanford C. Bernstein raised their price target on CVS Health from $94.00 to $106.00 and gave the stock an “outperform” rating in a report on Tuesday, May 12th. JPMorgan Chase & Co. raised their price target on CVS Health from $101.00 to $111.00 and gave the stock an “overweight” rating in a report on Tuesday, May 12th. UBS Group lifted their target price on CVS Health from $97.00 to $100.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Finally, Morgan Stanley lifted their target price on CVS Health from $93.00 to $106.00 and gave the stock an “overweight” rating in a report on Thursday, May 14th. Twenty-two equities research analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. According to data from MarketBeat, CVS Health has a consensus rating of “Moderate Buy” and a consensus target price of $98.68.

Trending Headlines about CVS Health

Here are the key news stories impacting CVS Health this week:

• Positive Sentiment: Bernstein reiterated an Outperform rating and raised its price target on CVS to $106, saying the company is well positioned for a Medicare Advantage turnaround. Bernstein Sees CVS Well Positioned for Medicare Advantage Turnaround
• Positive Sentiment: Glenview Capital said CVS has delivered about an 80% total return since May 2024, reinforcing confidence in the company’s operational turnaround and long-term investment case. Glenview Capital Issues Statement on CVS Health
• Neutral Sentiment: CVS announced a collaboration with America250 to support the nation’s 250th anniversary celebration, a brand-building move that is unlikely to have a major near-term effect on earnings. CVS Health Collaborates With America250 To Support the Nation’s 250th Anniversary Celebration
• Neutral Sentiment: Recent community and philanthropic announcements, including support for military families and senior housing, add to CVS’s public-facing story but are not likely to move the shares materially on their own. CVS Health, Diocese of Camden, and The Walters Group Unite to Bring Senior Affordable Housing to Williamstown, New Jersey
• Negative Sentiment: Three major hospital systems, including affiliates tied to Mount Sinai, the University of Michigan, and the University of Kansas, sued CVS, alleging it siphoned about $250 million from the 340B drug program through reduced reimbursements. Hospitals sue CVS for allegedly siphoning $250M in 340B funds
• Negative Sentiment: Separate reports say hospital systems are expanding the 340B dispute, raising the risk of more litigation, settlement costs, and reputational pressure for CVS’s pharmacy-benefit operations. CVS Health Lawsuits Test 340B Practices And Investor Risk Assessment
• Negative Sentiment: Director Larry Robbins disclosed several large stock sales over the past few days, including a roughly $187 million sale, which can weigh on investor sentiment even though he still owns a large stake. SEC Form 4 filing

CVS Health Trading Down 0.1%

CVS Health stock opened at $93.24 on Friday. The company has a quick ratio of 0.66, a current ratio of 0.87 and a debt-to-equity ratio of 0.78. CVS Health Corporation has a 52 week low of $58.50 and a 52 week high of $98.43. The company has a market capitalization of $118.97 billion, a price-to-earnings ratio of 41.08, a price-to-earnings-growth ratio of 0.91 and a beta of 0.60. The stock has a 50-day moving average price of $80.38 and a 200 day moving average price of $79.08.

CVS Health (NYSE:CVS) last released its earnings results on Wednesday, May 6th. The pharmacy operator reported $2.57 EPS for the quarter, topping analysts’ consensus estimates of $2.21 by $0.36. CVS Health had a return on equity of 11.88% and a net margin of 0.72%.The firm had revenue of $100.43 billion during the quarter, compared to the consensus estimate of $94.99 billion. During the same quarter in the previous year, the company posted $2.25 earnings per share. The company’s revenue was up 6.2% compared to the same quarter last year. CVS Health has set its FY 2026 guidance at 7.300-7.500 EPS. Sell-side analysts anticipate that CVS Health Corporation will post 7.44 EPS for the current year.

CVS Health Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Monday, May 4th. Shareholders of record on Thursday, April 23rd were issued a $0.665 dividend. The ex-dividend date of this dividend was Thursday, April 23rd. This represents a $2.66 dividend on an annualized basis and a yield of 2.9%. CVS Health’s payout ratio is presently 117.18%.

About CVS Health

CVS Health Corporation is a diversified healthcare company that operates a large network of retail pharmacies, pharmacy benefit management services and health care solutions. Headquartered in Woonsocket, Rhode Island, the company traces its roots to the early 1960s and has grown into an integrated provider of prescription drugs, over‑the‑counter products, clinical services and health insurance offerings. Its operating model combines retail pharmacy locations and in‑store clinics with broader pharmacy and health plan capabilities.

Key business activities include CVS Pharmacy retail operations, MinuteClinic walk‑in medical clinics and HealthHUB locations that offer expanded clinical services.